In this whitepaper, learn what targets are suitable, what are the trends in linkers and the drugs to be attached to the antibodies, what are the indications being pursued, how are companies dealing with the complexities of internalization and high cost of goods, what kind of data will drive an ADC licensing deal, how do the ADCs fit in the world of immuno-oncology and what is the future for ADCs.